Virtual Off-Target Screening

Cortex Discovery performs large-scale virtual off-target screening across 2,671 individual assays simultaneously, providing a comprehensive view of biological interactions far beyond a compound’s primary target.

Our platform delivers predictive accuracy on par with experimental screening while operating at dramatically greater speed and scale. These predictions are powered by a foundation model of pharmacological interactions trained on an extremely large experimental dataset spanning diverse compounds, targets, and assay systems.

By screening compounds across thousands of assays in parallel, potential off-target liabilities can be identified earlier, reducing the risk of costly preclinical failure and adverse effects in clinical development.

At the same time, broad assay coverage reveals potential secondary target effects that may support drug repurposing, uncover hidden mechanisms of action, or highlight beneficial polypharmacology signatures.

Unlike traditional experimental off-target profiling, which is expensive and limited in scope, Cortex Discovery enables rapid, scalable analysis across thousands of biological assays simultaneously.

Key Advantages

• 2,671 individual assays screened simultaneously
• Predictive accuracy comparable to experimental assays
• Early identification of off-target safety risks
• Discovery of secondary targets and repurposing opportunities
• Faster and more scalable than broad experimental screening

By combining broad biological coverage with experimentally grounded AI models, Cortex Discovery transforms off-target analysis.